ClinicalTrials.gg
CompletedNCT02891330IRCOUpdated Apr 21, 2021

Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity

An interventional study of Dietary and nutritional recommendations conducted by a nurse in Dumping Syndrome, sponsored by University Hospital, Lille. Completed at 4 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-21.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The postprandial dumping syndrome is a frequent consequence of Roux-en-Y Gastric ByPass due to the rapid emptying of the stomach remnant in to the intestinal lumen. Dumping-related symptoms occur very early after eating (within 30 minutes), are not associated with concurrent hypoglycemia, and are most prominent in the early postoperative period. This syndrome very debilitating for the patient can be improved by dietary and nutritional recommendations. We hypothesize that a personalized approach based on dietary and nutritional recommendations conducted by a nurse would likely to decrease the frequency of dumping syndrome and improve the postoperative quality of life of patients in the early postoperative period.

Read the detailed description

The Roux-en-Y Gastric ByPass is considered the gold standard of weight loss surgery and is the most commonly performed bariatric procedure worldwide.The postprandial dumping syndrome is a frequent consequence of gastrojejunal anastomosis due to the rapid emptying of the stomach remnant in to the intestinal lumen. Dumping-related symptoms occur very early after eating (within 30 minutes), are not associated with concurrent hypoglycemia, and are most prominent in the early postoperative period. The symptoms of dumping syndrome include nausea, abdominal cramps, diarrhea, dizzy spells, weakness and cold sweats either with or after eating.This syndrome very debilitating for the patient can be improved by dietary and nutritional recommendations. We hypothesize that an individualized approach based on dietary and nutritional recommendations and monitoring of patients conducted by a nurse in the first three months after surgery would likely to decrease these problems and improve the postoperative quality of life of patients.

02

Conditions studied

  • Dumping Syndrome

Browse trials for

Keywords

  • Roux-en-Y Gastric ByPass
03

In context

Dumping Syndrome

20 studies on the registry are indexed under Dumping Syndrome; 3 are open to participants now.

This study's enrollment of 135 is above the median of 30 across 17 interventional studies indexed under Dumping Syndrome.

Browse Dumping Syndrome studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥40 kg / m2 or ≥35 kg / m2 in the presence of comorbidities related to obesity
  • Indication to Roux-en-Y Gastric ByPass

Exclusion criteria

Exclusion Criteria:

  • to Roux-en-Y Gastric ByPass
  • Refusal to sign the consent form
  • Patient not affiliated to a social security system
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Dietary and nutritional recommendations

    Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse

    Behavioral: Dietary and nutritional recommendations conducted by a nurse

  • No intervention
    Standard of care

    Postoperative standard of care

Interventions

  • BehavioralDietary and nutritional recommendations conducted by a nurse

    Supplementary dietary and nutritional education

06

What researchers measure

Primary outcomes

  1. The frequency of dumping syndrome

    The frequency of dumping syndrome at 3 months will be compared between the two groups.

    Time frame: 3 months

Secondary outcomes

  1. Change in Body Mass Index

    Time frame: 3 months

  2. Frequence of Adverse Events after surgery

    Time frame: at 1 and 3 months

  3. Quality of Life-Lite questionnaire

    Estimation of quality of life by Impact of Weight on Quality of Life-Lite questionnaire(IWQOL-Lite)

    Time frame: 3 months

  4. Personal Effectiveness Assessment questionnaire (SEPOB)

    Measure the efficacy of therapeutic education by personal estimation of the level of skill using a specific obesity assessment questionnaire (SEPOB questionnaire or survey emotional, cognitive and behavioral sense of personal efficacy)

    Time frame: 3 months

07

Study locations

4 sites
  • CH ARRAS
    Arras, France
  • Ch Boulogne-Sur-Mer
    Boulogne Sur Mer, 62321, France
  • Hôpital Claude Huriez, CHRU
    Lille, France
  • Ch de Valenciennes
    Valenciennes, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Dec 2020, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2016
First posted
Sep 7, 2016
StartActual
Mar 2, 2017
Primary completionActual
Dec 18, 2020
CompletionActual
Dec 18, 2020
Last update
Apr 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02891330
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Mar 2, 2017
Primary completion
Dec 18, 2020
Completion
Dec 18, 2020
Last update
Apr 21, 2021

Study contacts

Hélène VERKINDT, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion